The CEO's sale was pre-planned under 10b5-1 and the director's sale followed option exercises, both small relative to market cap. No bearish signal from these trades; monitor next 8-K for any change in insider selling patterns.
Drugs in focus
MIRM drug pipeline →brelovitug
▲ Bullish Named in this insider cluster- Impact
- Phase
- Phase 3 (completed)
- Time to market
- Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
- Next catalyst
- BLA filing · H1 2027
What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.
Price Chart
How similar events traded
Executive Summary
Two Mirum insiders sold a combined $2.83M in open-market sales within a week of the company reporting strong Q3 results and raising guidance. CEO Peetz sold $1.80M under a 10b5-1 plan; Director Brege sold $1.03M without a plan after exercising options. The sales total 0.05% of market cap, below the 0.1% materiality threshold, and the CEO's plan sale is routine.
Key Financial Metrics
Key Facts
- CEO Christopher Peetz sold 20,000 shares at $90.00 for $1.80M under a 10b5-1 plan on 2026-11-04
- Director Laura Brege sold 10,907 shares at $94.05 for $1.03M (no 10b5-1 plan) on 2026-11-11
- Brege also exercised 14,167 shares at $0 and 14,167 shares at $16.71 on the same day
- Total open-market sales: $2.83M, representing 0.05% of $6.2B market cap
- Q3 2026 net product sales were $185.7M (+39.6% YoY) and full-year guidance raised to $715M-$720M
- FDA approval for ATEBRIOZ (zilurgisertib) in FOP was received
Financial Impact
Insider sales of $2.83M, 0.05% of market cap
Risk Factors
- Director Brege sold without a 10b5-1 plan, which could indicate personal liquidity needs
- Insider sales following strong earnings may raise questions if they accelerate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MIRM-1794606926144 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Viewing Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers